Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 1
2010 3
2011 2
2012 4
2013 5
2014 2
2015 5
2016 7
2017 3
2018 4
2019 7
2020 3
2021 3
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration.
Gabrielle PH, Delyfer MN, Glacet-Bernard A, Conart JB, Uzzan J, Kodjikian L, Arndt C, Tadayoni R, Soudry-Faure A, Creuzot Garcher CP. Gabrielle PH, et al. Ophthalmology. 2023 Sep;130(9):947-957. doi: 10.1016/j.ophtha.2023.04.014. Epub 2023 Apr 22. Ophthalmology. 2023. PMID: 37088447 Free article. Clinical Trial.
DESIGN: Randomized, open-label, multicenter superiority study. PARTICIPANTS: Ninety patients with neovascular age-related macular degeneration (nAMD) 50 years of age or older with recent SMH ( 14 days) of more than 2 optic disc areas and predomi …
DESIGN: Randomized, open-label, multicenter superiority study. PARTICIPANTS: Ninety patients with neovascular age-related m …
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
Yazdi MH, Faramarzi MA, Nikfar S, Falavarjani KG, Abdollahi M. Yazdi MH, et al. Expert Opin Biol Ther. 2015;15(9):1349-58. doi: 10.1517/14712598.2015.1057565. Epub 2015 Jun 16. Expert Opin Biol Ther. 2015. PMID: 26076760 Review.
INTRODUCTION: Wet age-related macular degeneration (AMD) is a potentially blinding eye disease that causes vision loss among individuals > 50 years old. ...AREAS COVERED: For this review, a literature search from 2011 to present was performed using …
INTRODUCTION: Wet age-related macular degeneration (AMD) is a potentially blinding eye disease that causes visio …
Neovascular age-related macular degeneration: decision making and optimal management.
Harding SP. Harding SP. Eye (Lond). 2010 Mar;24(3):497-505. doi: 10.1038/eye.2009.316. Epub 2010 Jan 8. Eye (Lond). 2010. PMID: 20057511 Review.
AIM: To review the decision-making processes and dilemmas in the delivery of services for neovascular age-related macular degeneration (nAMD) and describe its optimal management. ...CONCLUSIONS: Owing to incomplete evidence base health professionals …
AIM: To review the decision-making processes and dilemmas in the delivery of services for neovascular age-related macular …
Long-acting intraocular Delivery strategies for biological therapy of age-related macular degeneration.
Iyer S, Radwan AE, Hafezi-Moghadam A, Malyala P, Amiji M. Iyer S, et al. J Control Release. 2019 Feb 28;296:140-149. doi: 10.1016/j.jconrel.2019.01.007. Epub 2019 Jan 17. J Control Release. 2019. PMID: 30660630 Review.
As one of the leading causes of central vision loss in elderly population, worldwide cases of age-related macular degeneration (AMD) have seen a dramatic increase over the past several years. ...Some clinical examples include monthly intravitreal admin …
As one of the leading causes of central vision loss in elderly population, worldwide cases of age-related macular de …
Emotional and physical experiences of people with neovascular age-related macular degeneration during the injection process in Germany: a qualitative study.
Thier A, Breuning M, Wolfram C, Zeitz O, Holmberg C. Thier A, et al. BMJ Open. 2022 Jun 15;12(6):e058266. doi: 10.1136/bmjopen-2021-058266. BMJ Open. 2022. PMID: 35705348 Free PMC article.
OBJECTIVES: In order to better understand the continued barriers to the provision of vascular endothelial inhibitor therapy, this study aims to investigate patients' experiences with neovascular age-related macular degeneration (nvAMD) in Germany durin …
OBJECTIVES: In order to better understand the continued barriers to the provision of vascular endothelial inhibitor therapy, this study aims …
Additive Value of a Face-to-Face Visit to Virtual Remote Decision in Patients with Neovascular Age-Related Macular Degeneration.
Zvi D, Zur D, Schwartz S, Cohen S, Saranga A, Loewenstein A, Goldstein M. Zvi D, et al. Ophthalmologica. 2022;245(4):385-392. doi: 10.1159/000522273. Epub 2022 Feb 3. Ophthalmologica. 2022. PMID: 35114671 Free article.
INTRODUCTION: The increasing high prevalence of neovascular age-related macular degeneration (nvAMD) in the aging population combined with the need for frequent monitoring and treatment for many years, especially in the COVID-19 era, raises the need to …
INTRODUCTION: The increasing high prevalence of neovascular age-related macular degeneration (nvAMD) in the agin …
Intravitreal aflibercept for neovascular age-related macular degeneration.
Xu D, Kaiser PK. Xu D, et al. Immunotherapy. 2013 Feb;5(2):121-30. doi: 10.2217/imt.12.158. Immunotherapy. 2013. PMID: 23413903
Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in patients over the age of 50 in the western world. ...Having received US FDA approval for neovascular AMD in November 2011, aflibercept given every 8 we …
Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in patients over the …
Can intravitreal ranibizumab alter retrobulbar circulation in eyes with age-related macular degeneration?
Yuksel K, Altinkaynak H, Kina A, Kara N, Yazici AT, Demirok A. Yuksel K, et al. J Ocul Pharmacol Ther. 2013 Oct;29(8):723-7. doi: 10.1089/jop.2013.0051. Epub 2013 Jul 5. J Ocul Pharmacol Ther. 2013. PMID: 23829173 Clinical Trial.
PURPOSE: To determine the effect of a single intravitreal ranibizumab injection on retrobulbar circulation in cases with neovascular age-related macular degeneration (AMD). METHODS: In this prospective and interventional study, 32 patients with …
PURPOSE: To determine the effect of a single intravitreal ranibizumab injection on retrobulbar circulation in cases with neovascular …
Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA, Rosenfeld PJ. Ciulla TA, et al. Curr Opin Ophthalmol. 2009 May;20(3):166-74. doi: 10.1097/ICU.0b013e328329d173. Curr Opin Ophthalmol. 2009. PMID: 19381089 Review.
This review describes anti-VEGF strategies that are being evaluated in ocular diseases, other than neovascular age-related macular degeneration, in which neovascularization plays a critical role in pathogenesis. RECENT FINDINGS: Early studies of the an …
This review describes anti-VEGF strategies that are being evaluated in ocular diseases, other than neovascular age-related …
Evaluating an automated machine learning model that predicts visual acuity outcomes in patients with neovascular age-related macular degeneration.
Abbas A, O'Byrne C, Fu DJ, Moraes G, Balaskas K, Struyven R, Beqiri S, Wagner SK, Korot E, Keane PA. Abbas A, et al. Graefes Arch Clin Exp Ophthalmol. 2022 Aug;260(8):2461-2473. doi: 10.1007/s00417-021-05544-y. Epub 2022 Feb 5. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 35122132 Free PMC article.
PURPOSE: Neovascular age-related macular degeneration (nAMD) is a major global cause of blindness. Whilst anti-vascular endothelial growth factor (anti-VEGF) treatment is effective, response varies considerably between individuals. Thus, patients fa …
PURPOSE: Neovascular age-related macular degeneration (nAMD) is a major global cause of blindness. Whilst anti-v …
55 results